Correlation Between Editas Medicine and Crispr Therapeutics
Can any of the company-specific risk be diversified away by investing in both Editas Medicine and Crispr Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Editas Medicine and Crispr Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Editas Medicine and Crispr Therapeutics AG, you can compare the effects of market volatilities on Editas Medicine and Crispr Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Editas Medicine with a short position of Crispr Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Editas Medicine and Crispr Therapeutics.
Diversification Opportunities for Editas Medicine and Crispr Therapeutics
0.02 | Correlation Coefficient |
Significant diversification
The 3 months correlation between Editas and Crispr is 0.02. Overlapping area represents the amount of risk that can be diversified away by holding Editas Medicine and Crispr Therapeutics AG in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Crispr Therapeutics and Editas Medicine is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Editas Medicine are associated (or correlated) with Crispr Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Crispr Therapeutics has no effect on the direction of Editas Medicine i.e., Editas Medicine and Crispr Therapeutics go up and down completely randomly.
Pair Corralation between Editas Medicine and Crispr Therapeutics
Given the investment horizon of 90 days Editas Medicine is expected to under-perform the Crispr Therapeutics. In addition to that, Editas Medicine is 1.04 times more volatile than Crispr Therapeutics AG. It trades about -0.33 of its total potential returns per unit of risk. Crispr Therapeutics AG is currently generating about 0.03 per unit of volatility. If you would invest 4,600 in Crispr Therapeutics AG on August 24, 2024 and sell it today you would earn a total of 29.00 from holding Crispr Therapeutics AG or generate 0.63% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Insignificant |
| Accuracy | 100.0% |
| Values | Daily Returns |
Editas Medicine vs. Crispr Therapeutics AG
Performance |
| Timeline |
| Editas Medicine |
| Crispr Therapeutics |
Editas Medicine and Crispr Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Editas Medicine and Crispr Therapeutics
The main advantage of trading using opposite Editas Medicine and Crispr Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Editas Medicine position performs unexpectedly, Crispr Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Crispr Therapeutics will offset losses from the drop in Crispr Therapeutics' long position.| Editas Medicine vs. ZyVersa Therapeutics | Editas Medicine vs. Sonnet Biotherapeutics Holdings | Editas Medicine vs. Zura Bio Limited | Editas Medicine vs. Phio Pharmaceuticals Corp |
| Crispr Therapeutics vs. Beam Therapeutics | Crispr Therapeutics vs. Editas Medicine | Crispr Therapeutics vs. Caribou Biosciences | Crispr Therapeutics vs. Verve Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.
Other Complementary Tools
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities |